Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HSD-016

Phase 1 Completed 74 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedSingle-groupDouble-blindTreatment

Summary

This is a single ascending dose study of HSD-016 to provide the initial assessment of the safety, tolerability, how the drug is absorbed and eliminated, and its effect on the body.

Timeline

Start: 2008-09
Primary completion: 2009-02
Completion: 2009-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	HSD-016	Small molecule	—	Oral

Indications

No indication recorded.